[January 11, 2013]

Research and Markets: PharmaPoint: Seasonal Influenza Vaccines United States Drug Forecast and Market Analysis

Research and Markets (http://www.researchandmarkets.com/research/w9jj3r/pharmapoint) has announced the addition of GlobalData's new report "PharmaPoint: Seasonal Influenza Vaccines United States Drug Forecast and Market Analysis" to their offering.

Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi's Fluzone and Vaxigrip, GlaxoSmithKline's Fluarix and FluLaval and Novartis' Fluvirin garner the majority stake of the market.

However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca's intranasal FluMist and Sanofi's Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers that launch quadrivalent formulations will stea market share, patient share, and revenue from the trivalent influenza vaccines currently available.

The US influenza vaccine market is valued at approximately $1.05 billion in 2012. The projected drivers for market growth include increased patient awareness on the importance of being vaccinated against influenza, the introduction of vaccines with a quadrivalent formulation, a growing elderly population, and introduction of vaccines with improved efficacy in elderly patients.

Sanofi is the current market leader. It was among the first influenza vaccines available in the US, and it has produced a diverse portfolio of influenza vaccines under Sanofi's Fluzone brand. This brand includes trivalent vaccines with novel routes of administration (Fluzone ID) and vaccines with enhanced immunogenicity in elderly recipients (Fluzone High-Dose).

Scope

- Overview of seasonal influenza, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in the US from 2012 to 2022.

- Analysis of the impact of key events as well the drivers and restraints affecting the US seasonal influenza market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of the competition by understanding the changing competitive landscape for seasonal influenza

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of drug performance

- Obtain sales forecast for drugs from 2012 to 2022 in the US.

For more information visit http://www.researchandmarkets.com/research/w9jj3r/pharmapoint

Source (News - Alert): GlobalData

[ InfoTech Spotlight's Homepage ]